Patel Sushil
- SEC CIK
- 0001860609
In the past year, 4 open-market sale filings worth $1.86M and no purchases.
Current role at each company
- REPL Replimune Group, Inc.Chief Executive Officeras of Aug 12, 2026
- RVMD Revolution Medicines, Inc.Directoras of Jul 1, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $1.86M
- 4 filings
- Net
- −$1.86M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Patel Sushil as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
REPL Replimune Group, Inc.
Chief Executive Officer9 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 (view filing)5:07 PM ET | Aug 10 | 2 days | Patel SushilChief Executive Officer | SSale | −39.3K | $12.97 | −$510.3K | −5.3%708.2K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Patel SushilChief Executive Officer | SSale | −37.3K | $5.08 | −$189.6K | −4.8%747.5K after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Patel SushilChief Executive Officer | SSale | −10.0K | $11.13 | −$111.3K | −2.9%333.6K after | 10b5-1 |
| May 22, 2025 (view filing) | May 20 | 2 days | Patel SushilChief Executive Officer | SSale | −25.1K | $8.06 | −$202.3K | −6.8%343.6K after | |
| Dec 18, 2024 (view filing) | Dec 16 | 2 days | Patel SushilChief Executive Officer | SSale | −10.0K | $12.42 | −$124.2K | −4.7%202.0K after | 10b5-1 |
| May 20, 2024 (view filing) | May 16 | 4 days | Patel SushilChief Executive Officer | SSale | −20.2K | $6.47 | −$130.7K | −8.7%212.0K after | |
| Jun 15, 2023 (view filing) | Jun 13 | 2 days | Patel SushilChief Strategy Officer | SSale | −5.70K | $24.04 | −$137.0K | −3.7%148.9K after | 2 lots10b5-1 |
| May 18, 2023 (view filing) | May 16 | 2 days | Patel SushilChief Strategy Officer | SSale | −15.6K | $18.05 | −$281.1K | −9.2%154.6K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Patel SushilChief Commercial Officer | SSale | −10.7K | $14.59 | −$155.9K | −7.6%130.1K after |
RVMD Revolution Medicines, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)6:25 PM ET | Jun 29 | 2 days | Patel SushilDirector | SSale | −5.58K | $187.99 | −$1.05M | −20.5%21.7K after | 9 lots10b5-1 |
| Nov 4, 2024 (view filing) | Oct 31 | 4 days | Patel SushilDirector | SSale | −5.00K | $54.14 | −$270.7K | −20.0%19.9K after | 10b5-1 |
| Jul 10, 2024 (view filing) | Jul 9 | 1 day | Patel SushilDirector | SSale | −2.15K | $44.00 | −$94.8K | −9.7%19.9K after | 10b5-1 |
| Apr 12, 2024 (view filing) | Apr 10 | 2 days | Patel SushilDirector | SSale | −2.15K | $37.00 | −$79.7K | −12.1%15.7K after | 10b5-1 |